158 related articles for article (PubMed ID: 17913796)
21. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.
Pfeifer ND; Bridges AS; Ferslew BC; Hardwick RN; Brouwer KL
J Pharmacol Exp Ther; 2013 Dec; 347(3):737-45. PubMed ID: 24080682
[TBL] [Abstract][Full Text] [Related]
22. The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.
Bedada SK; Boga PK
Eur J Clin Pharmacol; 2017 Mar; 73(3):343-349. PubMed ID: 27981349
[TBL] [Abstract][Full Text] [Related]
23. Mrp2 is involved in benzylpenicillin-induced choleresis.
Ito K; Koresawa T; Nakano K; Horie T
Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G42-9. PubMed ID: 15194559
[TBL] [Abstract][Full Text] [Related]
24. Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2.
Hidemura K; Zhao YL; Ito K; Nakao A; Tatsumi Y; Kanazawa H; Takagi K; Ohta M; Hasegawa T
Antimicrob Agents Chemother; 2003 May; 47(5):1636-42. PubMed ID: 12709333
[TBL] [Abstract][Full Text] [Related]
25. Hepatobiliary disposition of thyroid hormone in Mrp2-deficient TR- rats: reduced biliary excretion of thyroxine glucuronide does not prevent xenobiotic-induced hypothyroidism.
Lecureux L; Dieter MZ; Nelson DM; Watson L; Wong H; Gemzik B; Klaassen CD; Lehman-McKeeman LD
Toxicol Sci; 2009 Apr; 108(2):482-91. PubMed ID: 19211616
[TBL] [Abstract][Full Text] [Related]
26. Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).
Jäger W; Gehring E; Hagenauer B; Aust S; Senderowicz A; Thalhammer T
Life Sci; 2003 Oct; 73(22):2841-54. PubMed ID: 14511769
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2.
Ruiz ML; Villanueva SS; Luquita MG; Sánchez-Pozzi EJ; Crocenzi FA; Pellegrino JM; Ochoa JE; Vore M; Mottino AD; Catania VA
Biochem Pharmacol; 2005 Feb; 69(3):531-9. PubMed ID: 15652244
[TBL] [Abstract][Full Text] [Related]
28. Effect of probenecid on the biliary excretion of belotecan.
Namkoong EM; Kim IW; Kim DD; Chung SJ; Shim CK
Arch Pharm Res; 2007 Nov; 30(11):1482-8. PubMed ID: 18087819
[TBL] [Abstract][Full Text] [Related]
29. Hepatobiliary excretion of dipyrrinone sulfonates in Mrp2-deficient (TR(-)) rats.
McDonagh AF; Lightner DA; Boiadjiev SE; Brower JO; Norona WS
Bioorg Med Chem Lett; 2002 Sep; 12(17):2483-6. PubMed ID: 12161163
[TBL] [Abstract][Full Text] [Related]
30. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.
Ando T; Kusuhara H; Merino G; Alvarez AI; Schinkel AH; Sugiyama Y
Drug Metab Dispos; 2007 Oct; 35(10):1873-9. PubMed ID: 17639028
[TBL] [Abstract][Full Text] [Related]
31. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions.
Patel NJ; Zamek-Gliszczynski MJ; Zhang P; Han YH; Jansen PL; Meier PJ; Stieger B; Brouwer KL
Mol Pharmacol; 2003 Jul; 64(1):154-9. PubMed ID: 12815171
[TBL] [Abstract][Full Text] [Related]
32. Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.
Turncliff RZ; Hoffmaster KA; Kalvass JC; Pollack GM; Brouwer KL
J Pharmacol Exp Ther; 2006 Aug; 318(2):881-9. PubMed ID: 16690724
[TBL] [Abstract][Full Text] [Related]
33. Abolition of valproate-derived choleresis in the Mrp2 transporter-deficient rat.
Wright AW; Dickinson RG
J Pharmacol Exp Ther; 2004 Aug; 310(2):584-8. PubMed ID: 15075379
[TBL] [Abstract][Full Text] [Related]
34. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
Vlaming ML; Mohrmann K; Wagenaar E; de Waart DR; Elferink RP; Lagas JS; van Tellingen O; Vainchtein LD; Rosing H; Beijnen JH; Schellens JH; Schinkel AH
J Pharmacol Exp Ther; 2006 Jul; 318(1):319-27. PubMed ID: 16611851
[TBL] [Abstract][Full Text] [Related]
35. Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2.
Johnson DR; Habeebu SS; Klaassen CD
Toxicol Sci; 2002 Mar; 66(1):16-26. PubMed ID: 11861969
[TBL] [Abstract][Full Text] [Related]
36. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics.
Kato Y; Takahara S; Kato S; Kubo Y; Sai Y; Tamai I; Yabuuchi H; Tsuji A
Drug Metab Dispos; 2008 Jun; 36(6):1088-96. PubMed ID: 18339814
[TBL] [Abstract][Full Text] [Related]
37. Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs.
Sjögren E; Hedeland M; Bondesson U; Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():214-23. PubMed ID: 24075962
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.
Yang K; Brouwer KL
Drug Metab Dispos; 2014 Jul; 42(7):1219-26. PubMed ID: 24799397
[TBL] [Abstract][Full Text] [Related]
39. Role of rat multidrug resistance protein 2 in plasma and biliary disposition of dibromosulfophthalein after microsomal enzyme induction.
Johnson DR; Klaassen CD
Toxicol Appl Pharmacol; 2002 Apr; 180(1):56-63. PubMed ID: 11922777
[TBL] [Abstract][Full Text] [Related]
40. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.
Yanni SB; Augustijns PF; Benjamin DK; Brouwer KL; Thakker DR; Annaert PP
Drug Metab Dispos; 2010 Oct; 38(10):1848-56. PubMed ID: 20606004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
